Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):259–260. doi: 10.1038/bjc.1989.54

CA125 in ovarian tumour tissue at second laparotomy.

T S Maughan 1, R G Fish 1, M D Shelley 1, B Jasani 1, G T Williams 1, M Adams 1
PMCID: PMC2247003  PMID: 2649131

Full text

PDF
259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez R. D., To A., Boots L. R., Shingleton H. M., Hatch K. D., Hubbard J., Soong S. J., Potter M. E. CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol. 1987 Mar;26(3):284–289. doi: 10.1016/0090-8258(87)90019-9. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fish R. G., Shelley M. D., Maughan T., Rocker I., Adams M. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy. Eur J Cancer Clin Oncol. 1987 Jun;23(6):831–835. doi: 10.1016/0277-5379(87)90287-2. [DOI] [PubMed] [Google Scholar]
  5. Fleuren G. J., Nap M., Aalders J. G., Trimbos J. B., de Bruijn H. W. Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer. 1987 Nov 15;60(10):2437–2442. doi: 10.1002/1097-0142(19871115)60:10<2437::aid-cncr2820601015>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  6. Kabawat S. E., Bast R. C., Welch W. R., Knapp R. C., Colvin R. B. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 1983 Jan;79(1):98–104. doi: 10.1093/ajcp/79.1.98. [DOI] [PubMed] [Google Scholar]
  7. Koelma I. A., Nap M., Rodenburg C. J., Fleuren G. J. The value of tumour marker CA 125 in surgical pathology. Histopathology. 1987 Mar;11(3):287–294. doi: 10.1111/j.1365-2559.1987.tb02633.x. [DOI] [PubMed] [Google Scholar]
  8. Maughan T. S., Fish R. G., Shelley M., Jasani B., Williams G. T., Adams M. Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary. Gynecol Oncol. 1988 Jul;30(3):342–346. doi: 10.1016/0090-8258(88)90248-x. [DOI] [PubMed] [Google Scholar]
  9. Niloff J. M., Bast R. C., Jr, Schaetzl E. M., Knapp R. C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol. 1985 Apr 1;151(7):981–986. doi: 10.1016/0002-9378(85)90678-7. [DOI] [PubMed] [Google Scholar]
  10. Raghavan D., Gibbs J., Nogueira Costa R., Kohn J., Orr A. H., Barrett A., Peckham M. J. The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br J Cancer Suppl. 1980 Apr;4:191–194. [PMC free article] [PubMed] [Google Scholar]
  11. Shelley M. D., Fish R. G. Evaluation of an immunoradiometric assay for the detection of an ovarian tumour marker, CA125, in serum. Ann Clin Biochem. 1986 May;23(Pt 3):292–296. doi: 10.1177/000456328602300308. [DOI] [PubMed] [Google Scholar]
  12. Ward A. M. The value of markers in fine tuning of chemotherapy. Cancer Treat Rev. 1987 Dec;14(3-4):401–405. doi: 10.1016/0305-7372(87)90037-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES